Skip to main content

TAK-755-2001 A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Hematology

Awarded By

Takeda Development Center Americas, Inc

Start Date

March 15, 2023

End Date

December 15, 2026
 

Administered By

Medicine, Hematology

Awarded By

Takeda Development Center Americas, Inc

Start Date

March 15, 2023

End Date

December 15, 2026